Halozyme
HALO
313 hedge funds and large institutions have $5.87B invested in Halozyme in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 125 increasing their positions, 110 reducing their positions, and 47 closing their positions.
24% more call options, than puts
Call options by funds: $24.5M | Put options by funds: $19.7M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
14% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 110
7% more capital invested
Capital invested by funds: $5.51B → $5.87B (+$366M)
6.72% less ownership
Funds ownership: 97.84% → 91.11% (-6.7%)
7% less funds holding
Funds holding: 336 → 313 (-23)
40% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$32.4M |
| 2 |
BlackRock
New York
|
+$27.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$17.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$34.9M |
| 2 |
Goldman Sachs
New York
|
-$30M |
| 3 |
Renaissance Technologies
New York
|
-$28.1M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$20.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$19.1M |
HALO Hedge Fund Activity: Q2 2021 in Review
313 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2021, worth a combined $5.87B — up 6.6% from $5.51B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of HALO and 28 opened new positions — a net loss of 19 holders — while 110 trimmed existing stakes and 125 added.
The largest buyer was Macquarie Group, adding an estimated $32.4M. The largest seller was Bellevue Group, cutting an estimated $34.9M.
- 313 institutional investors held Halozyme (HALO) as of Q2 2021, down from 336 in Q1 2021.
- Funds reported $5.87B of Halozyme stock for Q2 2021, up 6.6% quarter-over-quarter.
- 28 funds opened new Halozyme positions in Q2 2021 and 47 closed out, a net change of -19 holders.
- The largest Halozyme buyer in Q2 2021 was Macquarie Group, an estimated $32.4M added.
- The largest Halozyme seller in Q2 2021 was Bellevue Group, an estimated $34.9M sold.
Based on aggregated 13F filings for Q2 2021.